Preview Mode Links will not work in preview mode

Nov 24, 2020

Featuring a discussion on recent data with CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer with Prof Stephen Johnston, including the following topics:

  • Management of Localized ER-Positive, HER2-Negative Early Breast Cancer: Recent Advances in Adjuvant Systemic Endocrine-Based Therapies — Stephen Johnston, MA, PhD (0:00)
  • Case: A postmenopausal woman in her mid-50s with high-risk ER-positive, HER2-negative breast cancer who receives abemaciclib in addition to standard adjuvant hormonal therapy on the monarchE trial (24:37)
  • Case: A woman in her mid-40s with recurrent ER-positive, HER2-negative breast cancer and oligometastatic disease to the bones (29:14)
  • Case: A premenopausal woman in her mid-40s with ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score® of 19 (33:07)

CME information and select publications